Mitochondria are best known for producing ATP, but a small family of peptides encoded within the mitochondrial genome itself — separate from the nuclear DNA that codes for most cellular proteins — has become its own research niche over the last two decades. These are the mitochondrial-derived peptides, or MDPs: Humanin, discovered in 2001, followed by MOTS-c in 2015, and the six SHLP peptides characterized starting in 2016. Each is encoded in a different stretch of mitochondrial rRNA, and each has developed a distinct research identity. Researchers evaluating which MDP fits a given experimental question need to understand where these peptides diverge, not just that they share an unusual origin.
Same genome, different jobs
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region, first isolated and characterized in 2015. Humanin, a 21-24 amino acid peptide (depending on the analog), comes from the 16S rRNA region and has the longest publication history of the group. The SHLP family — SHLP1 through SHLP6 — are shorter peptides (as few as 6 amino acids) also encoded in the 16S rRNA region and characterized more recently, with comparatively less published data behind them.
What makes this family interesting to researchers isn't just that they share a mitochondrial origin — it's that they appear to signal outward from the mitochondrion to influence cell-wide and even organism-wide processes, a phenomenon sometimes called mitochondrial-to-nuclear communication. Each peptide, however, has been mapped to a different primary signaling role.
MOTS-c: the metabolic specialist
The bulk of MOTS-c research centers on AMPK (AMP-activated protein kinase) activation and its downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. That makes MOTS-c the go-to MDP in the literature for metabolic pathway studies — high-fat-diet models, insulin resistance models, and skeletal muscle metabolism research all lean on MOTS-c specifically. A structurally distinguishing feature is that MOTS-c has been shown to translocate to the nucleus under cellular stress, where it appears to interact with gene regulatory elements — a dual cytoplasmic/nuclear behavior not yet demonstrated for Humanin or the SHLP peptides. MOTS-c expression also appears to respond to exercise in rodent skeletal muscle in published studies, which has driven interest in its role linking physical activity to metabolic adaptation at the cellular level.
Humanin: the neuroprotection specialist
Humanin's research trajectory runs in a different direction entirely. It was first identified for its ability to protect neurons from amyloid-beta toxicity in cell models, which placed it early in Alzheimer's-adjacent research. Its proposed mechanism runs through STAT3 activation and suppression of pro-apoptotic proteins such as BAX — an anti-apoptotic, cell-survival-oriented pathway that MOTS-c does not share as a primary research focus. Some Humanin studies have also identified interaction with the IGF-1 receptor system, giving it a partial metabolic research footprint, but the dominant published research context for Humanin remains neuroprotection and cell survival signaling rather than glucose/lipid metabolism.
The SHLP peptides: newer, less characterized
SHLP1 through SHLP6 were described by Cobb and colleagues in 2016 and represent the newest branch of the MDP family. Their short length — some as few as 6 amino acids — makes them straightforward to synthesize but limits the complexity of the molecular interactions they can support. SHLP2 in particular has drawn some research attention for cell-survival-promoting effects that overlap conceptually with Humanin, and other SHLP research has touched on mitochondrial-function maintenance and oxidative-damage protection. Compared to MOTS-c and Humanin, however, the published dataset on SHLP peptides is thin — researchers designing SHLP-based studies should factor that gap in prior data into their experimental design from the outset.
Choosing an MDP for a research question
- Skeletal muscle glucose uptake, AMPK pathway work, or high-fat-diet metabolic models — MOTS-c has the deepest published dataset here.
- Neuroprotection, amyloid-beta toxicity, or anti-apoptotic cell survival signaling — Humanin's research history is the most established for these questions.
- Aging biology framed around metabolic decline — MOTS-c dominates the rodent literature.
- Aging biology framed around neurodegeneration — Humanin is the more studied tool.
- Mitochondrial stress response and gene regulation — MOTS-c's nuclear translocation behavior is the differentiating data point.
- Exploratory or newer mechanistic territory — SHLP peptides are an option, with the caveat that far less prior literature exists to build on.
Do MOTS-c and Humanin interact?
A small but growing body of research has begun asking whether MOTS-c and Humanin — both produced within the same organelle and released into the same cellular environment — might act together as a coordinated signaling system rather than as fully independent peptides. Early in vitro work has suggested possible additive effects on some metabolic endpoints when both are present, though this remains preliminary and the mechanistic basis for any interaction is not yet well defined. It's a research direction worth watching as the MDP field matures, but not yet something with settled conclusions.
Practical considerations for comparative MDP research
Researchers running comparative studies across MDPs should keep a few methodological points in mind. Detection assays (ELISA, Western blot) need antibodies validated for specificity, since cross-reactivity between structurally related short peptides is a real risk. Because MOTS-c and Humanin differ substantially in potency and receptor engagement, dose-matching by mass rather than by biological equivalence can produce misleading comparisons. And cell-model selection matters: a line well suited to MOTS-c metabolic research (such as C2C12 myocytes) is not necessarily appropriate for Humanin neuroprotection work, which typically calls for neuronal models instead.
Sourcing MOTS-c for research
Comparative MDP work depends on purity you can actually verify — a mislabeled or degraded peptide will produce results that look mechanistic but are really just an artifact of poor sourcing. See HPLC purity analysis and how to read a COA for what to check before running comparative experiments, and the broader supplier checklist for vetting any peptide source.
V8 Peptides supplies MOTS-c as lyophilized powder verified to ≥98% purity by HPLC, with a batch-specific Certificate of Analysis. See the MOTS-c research vial product page for current specifications, and the MOTS-c research overview for a full mechanism summary.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.